ClinicalTrials.gg
RecruitingNCT07777744Updated Aug 20, 2026

Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation

An observational study in Ventricular Tachycardia (VT) and Premature Ventricular Complexes, sponsored by University Hospital, Basel, Switzerland. Recruiting at 25 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University Hospital, Basel, Switzerland · Observational

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
15,000
Ages
18 Years and older
Sex
All
01

Study summary

The investigators aim to characterize patients presenting with a severe ventricular tachycardia (VT) and premature ventricular complex (PVC)-ablation-related complication including patient characteristics, procedural details and subsequent management of the complication by gathering existing patient-level data.

02

Conditions studied

  • Ventricular Tachycardia (VT)
  • Premature Ventricular Complexes

Keywords

  • Ablation
03

In context

Tachycardia, Ventricular

451 studies on the registry are indexed under Tachycardia, Ventricular; 120 are open to participants now.

This study's planned enrollment of 15,000 is above the median of 167 across 147 observational studies indexed under Tachycardia, Ventricular.

Browse Tachycardia, Ventricular studies →

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients presenting with a severe VT/PVC-ablation-related complication

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Centers : Centers participating in the present collaborative study group. Invitation to participate will be based either upon personal referral of one of the investigator, previous collaboration or based on a meta-analytic review of the literature published on the subject within the past 20 years.
  • Patients: Females and males of >18 years undergoing any type of VT/PVC ablation. While we will accept redo-procedure we will ask for a unique patient-identifier to link procedures belonging to the same patients together.
  • Interventions: VT/PVC ablation (first intervention or re-do) as routinely performed by the participating centers
  • Outcomes: Severe complications, defined as hemodynamic instability requiring mechanical intensive-care management, tamponade, stroke, cardiac arrest, myocardial infarction, phrenic nerve palsies, major bleeding requiring transfusion, vascular or cardiac complication requiring surgery, procedure-related death.
  • Setting: Observational cohort studies, registries, retrospective cohort studies. Data stemming from RCTs (Randomized controlled trials) will not be collected as they likely do not represent a "real-life" setting.
  • Length of follow-up: Peri-procedural complications
  • Years considered: Not limited to a specific time-frame, but to reflect common ablation practices, we will focus on data from the 20 past years.
  • Number of patients provided : No lower limit of patients provided per dataset or ablation volume per year to include high- as well as low-volume centers

Exclusion criteria

Exclusion Criteria:

  • Refusal of the center to participate.
  • Less than 10 procedures available in the dataset (no case reports)
  • Missing essential baseline characteristics, missing collection of sufficient details regarding each complication.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
15,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Descriptive characterization of patients

    characterizing features: * hemodynamic instability requiring mechanical intensive-care management * tamponade * stroke * cardiac arrest * myocardial infarction * coronary artery dissection * phrenic nerve palsy * major bleeding as per the International Society on Thrombosis and Haemostasis (ISTH) * vascular or cardiac complication requiring surgery or interventional management (interventional radiology, angiology) * iatrogenic atrio-ventricular block requiring device implantation or upgrade. * procedure-related death

    Time frame: up to 30 days

Secondary outcomes

  1. Prevalence of each severe complication

    Time frame: up to 30 days

  2. Difference in baseline characteristics between the patients who experienced a complication and the ones who did not

    Time frame: up to 30 days

  3. The contribution of important baseline and procedural characteristics to the occurrence of a severe complication

    Time frame: up to 30 days

  4. Impact of center-specific data on the occurrence and management of these complications

    Case-load of the centers, number of electrophysiologists, geographic hospital location, routine use of ICE (Intracardiac Echocardiography)

    Time frame: up to 30 days

07

Study locations

25 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07777744
Responsible party
Sponsor
First posted
Aug 20, 2026
Start date
Jul 1, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Michael Kühne, Prof. Dr. med.
Contact
Michael.kuehne@usb.ch
0041 61 265 52 14
Patrick Badertscher, PD Dr. med.
Contact
Michael Kühne, Prof. Dr. med.
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion